Review of Management and Outcomes in Women with Thrombophilia Risk during Pregnancy at a Single Institution

• Published in: ISRN obstetrics and gynecology 2014, Vol.2014, p.381826-6
• Main Authors: Khalafallah, Alhossain A., Ibraheem, Abdul-Rauf O., Teo, Qiong Yue, AlBarzan, Abdul-Majeed, Parameswaran, Ramanathan, Hooper, Emily, Pavlov, Toly, Dennis, Amanda E., Hannan, Terry
• Format: Article
• Language: English
• Subjects: Anticoagulants; Clinical Study; Health risk assessment; Mortality; Mutation; Womens health
• ISSN: 2090-4436; 2090-4444; 2090-4444
• DOI: 10.1155/2014/381826

Pregnancy is a hypercoagulable state associated with an increased risk of venous thromboembolic disease (VTE). We retrospectively studied 38 Caucasian pregnant women with thrombophilia risk and compared their obstetric outcomes with a matched cohort without known thrombophilia risk during the period between January 2007 and December 2010. There were (2) cases with factor V Leiden, (6) prothrombin gene mutation, (1) antithrombin III deficiency, (2) protein C deficiency, (3) protein S deficiency, (10) MTHFR mutation, (7) anti-cardiolipin antibodies, and (1) lupus anticoagulant. Patients without thrombophilia who presented with recurrent unprovoked VTE were considered as high risk (6 cases). Most patients received anticoagulation (34/38) with aspirin only (6), enoxaparin (27), and warfarin (1). Twenty-six out of thirty-eight pregnant women (68.4%) with an increased risk of thrombophilia experienced one or more obstetric complications defined as hypertension, preeclampsia, placenta abruptio, VTE, and oligohydramnios, compared with 15 out of 40 (37.5%) pregnant women in the control group (OR 3.6; 95% CI 1.42, 9.21, P